Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: A nationwide study in the Netherlands

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2036-2042

  Vencken, P M L H ^a   Reitsma, W ^b   Kriege, M ^a   Mourits, M J E ^b   de Bock, G H ^b   de Hullu, J A ^c   van Altena, A M ^c   Gaarenstroom, K N ^d   Vasen, H F A ^e   Adank, M A ^f   Schmidt, M K ^g   van Beurden, M ^g   Zweemer, R P ^h   Rijcken, F ⁱ   Slangen, B F M ^j   Burger, C W ^a   Seynaeve, C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Foundation for the Detection of Hereditary Tumours   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

BRCA1; BRCA2; Chemotherapy; Ovarian cancer; Response; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; PACLITAXEL; PLATINUM COMPLEX;

ADULT; AGE; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT FREE INTERVAL; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UNIVERSITY HOSPITAL;

BRCA1; BRCA2; CHEMOTHERAPY; OVARIAN CANCER; RESPONSE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRCA1 PROTEIN; BRCA2 PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NETHERLANDS; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; SURVIVAL; TREATMENT OUTCOME;

EID: 84881237680     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt068     Document Type: Article

References (30)

1. Stratton JF, Pharoah P, Smith SK et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998; 105: 493-499.
2. Chappuis PO, Foulkes WD. Risk assessment and genetic testing. Cancer Treat Res 2002; 107: 29-59.
3. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-1365.
4. Risch HA, McLaughlin JR, Cole DE et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694-1706.
5. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654-2663.
6. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
7. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-1333.
8. Mavaddat N, Barrowdale D, Andrulis IL et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134-147.
9. Chetrit A, Hirsh-Yechezkel G, Ben-David Y et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008; 26: 20-25.
10. Tan DS, Rothermundt C, Thomas K et al. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 5530-5536.
11. Ragupathy K, Ferguson M. Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations. J Obstet Gynaecol 2011; 31: 178-179.
12. Vencken PM, Kriege M, Hoogwerf D et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011; 22: 1346-1352.
13. Cortez D, Wang Y, Qin J et al. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286: 1162-1166.
14. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001; 27: 247-254.
15. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283: 2260-2265.
16. Ben David Y, Chetrit A, Hirsh-Yechezkel G et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002; 20: 463-466.
17. Cass I, Baldwin RL, Varkey T et al. Improved survival in women with BRCAassociated ovarian carcinoma. Cancer 2003; 97: 2187-2195.
18. Yang D, Khan S, Sun Y et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306: 1557-1565.
19. Reitsma W, de Bock GH, Oosterwijk JC et al. Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?. Int J Gynecol Cancer 2012; 22: 579-585.
20. Bolton KL, Chenevix-Trench G, Goh C et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012; 307: 382-390.
21. Hyman DM, Zhou Q, Iasonos A et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1- associated serous ovarian cancer. Cancer 2012; 118: 3703-3709.
22. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009; 105: 3-4.
23. Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000; 87: 881-886.
24. Geskus RB. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring. Biometrics 2011; 67: 39-49.
25. Keiding N. Delayed entry. In Armitage PCT (ed), Encyclopedia of Biostatistics. Hoboken, NJ: John, Wiley & Sons 2005.
26. Gerestein CG, Eijkemans MJ, de Jong D et al. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 2009; 116: 372-380.
27. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
28. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-251.
29. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2519.
30. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392.